Reviva Pharmaceuticals (NASDAQ:RVPH) Earns Buy Rating from HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark reiterated a “speculative buy” rating and set a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $3.06 on Monday. The stock has a fifty day moving average price of $3.60 and a 200-day moving average price of $4.11. The company has a market cap of $85.44 million, a price-to-earnings ratio of -1.87 and a beta of -0.02. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RVPH. EMC Capital Management lifted its position in shares of Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after buying an additional 115,028 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth $72,000. Finally, Armistice Capital LLC increased its holdings in Reviva Pharmaceuticals by 194.0% in the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after purchasing an additional 1,164,000 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.